10-Q: Exicure Faces Financial Distress, Seeks Strategic Alternatives

Exicure, Inc. reported a net loss of $1.12 million for Q2 2026, with cash reserves insufficient for 12 months of operations, raising substantial doubt about its going concern status.

Summary

• Exicure, Inc. reported a net loss of $1.12 million for the three months ended June 30, 2026, and a net loss of $2.95 million for the six months ended June 30, 2026.
• The company's cash and cash equivalents stood at $1.717 million as of June 30, 2026, which management believes is insufficient to fund operations for the next 12 months.
• This liquidity situation raises substantial doubt about Exicure's ability to continue as a going concern.
• The company is actively evaluating a range of strategic alternatives to maximize stockholder value, including potential acquisitions, financings, and strategic partnerships.
• Research and development expenses decreased by 81% to $0.17 million for the three months ended June 30, 2026, compared to $0.93 million in the prior year period.
• General and administrative expenses also decreased by 41% to $0.89 million for the three months ended June 30, 2026, compared to $1.51 million in the prior year period.
• The company received a deficiency notice from Nasdaq regarding its stockholders' equity falling below the minimum requirement and has submitted a plan of compliance.
• Exicure is involved in ongoing legal proceedings, including an unlawful detainer action related to a sublease and a previously settled securities class action and derivative lawsuits.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing as highly negative due to significant financial distress, a going concern warning, and ongoing legal challenges, despite some operational cost reductions.

Positives

• Significant reduction in operating expenses, with R&D expenses down 81% and G&A expenses down 41% for the three months ended June 30, 2026, indicating cost control measures.
• Successful settlement of a securities class action lawsuit and derivative lawsuits, removing significant legal overhangs.
• The company is actively exploring strategic alternatives, which could potentially unlock shareholder value.
• Regained compliance with Nasdaq listing requirements related to delayed filing of its Q1 2026 Form 10-Q.

Negatives

• Substantial doubt about the company's ability to continue as a going concern due to insufficient cash reserves ($1.717 million) to fund operations for the next 12 months.
• Net loss of $1.12 million for Q2 2026 and $2.95 million for the first six months of 2026.
• Stockholders' Equity has fallen below Nasdaq's minimum requirement of $2.5 million, requiring a plan of compliance.
• The company is facing an unlawful detainer action from Dren Bio for unpaid rent, with a demand of approximately $0.7 million.
• The company deferred a $1 million milestone payment to GPCR, to be satisfied through the issuance of common stock, indicating cash constraints.

Risks

• Inability to raise additional capital, which could lead to bankruptcy protection or cessation of operations.
• Potential delisting from The Nasdaq Capital Market if the plan of compliance for the equity shortfall is not accepted or if further listing requirements are not met.
• Uncertainty regarding the outcome and success of the evaluation of strategic alternatives.
• Ongoing legal proceedings, including the unlawful detainer action, could result in material adverse effects.
• The company's limited cash resources and current financial condition may make it difficult to obtain financing on favorable terms, or at all.
• Potential dilution to existing stockholders if additional capital is raised through equity offerings.
• The company's ability to attract and retain qualified management and key personnel could be impacted by financial instability and turnover.
• Macroeconomic conditions, including inflation, capital market instability, and geopolitical events, could further impact the company's ability to raise capital and operate.

Future Outlook

The company's future outlook is highly uncertain due to its current financial condition and the need for additional financing. Management is exploring strategic alternatives, but there is substantial doubt about its ability to continue as a going concern. The company expects to incur significant expenses and negative cash flows for the foreseeable future and anticipates needing to raise capital through equity offerings, which may result in significant dilution.

Management Comments

• Management believes that the Company's existing cash and cash equivalents will not be sufficient to fund planned operations for at least the twelve-month period following issuance of these financial statements.
• Management believes that, given the Company's current cash position, operating plans and forecasted negative cash flows from operating activities over the next twelve months, there is substantial doubt about the Company's ability to continue as a going concern within one year after the date these condensed consolidated financial statements are issued.
• Management continues to evaluate potential equity financings, strategic transactions, partnering opportunities and other capital-raising alternatives.
• If we are unable to raise capital, the Company could seek bankruptcy protection and/or cease operations, which may result in our stockholders receiving no or very little value in respect of their shares of our common stock.

Industry Context

StockSavvy.ai notes that Exicure's situation is unfortunately common among early-stage biotechnology companies that struggle to secure consistent funding, especially when clinical development timelines are long and revenue generation is distant. The shift in focus from core R&D to exploring strategic alternatives and cost-cutting is a typical response to severe liquidity constraints.

Comparison to Industry Standards

• Many early-stage biotechnology companies face similar going concern issues, often requiring significant capital raises or strategic partnerships to advance drug candidates through clinical trials.
• Companies like Exicure often explore mergers, acquisitions, or licensing deals to leverage their technology or pipeline, as seen with Exicure's acquisition of GPCR USA and subsequent license agreement.
• The Nasdaq listing requirements, particularly the minimum stockholders' equity threshold, are standard for companies listed on major exchanges, and falling below them triggers a compliance process common across the industry.

Legal Proceedings

• Unlawful Detainer action filed by Dren Bio Management, Inc. against GPCR USA for approximately $0.7 million in unpaid rent and related charges.
• The company and certain current/former officers and directors were defendants in a securities class action (Colwell v. Exicure, Inc. et al.), which was settled for $5.625 million, funded by insurers.
• Three related stockholder derivative lawsuits (Puri v. Giljohann, et al.; Sim v. Giljohann, et al.; Stourbridge Investments LLC v. Exicure, Inc. et al.) were settled and dismissed.
• A former employee filed a complaint for breach of contract and unpaid wages, which was settled for $425,000.

Related Party Transactions

• The Company entered into a Consulting Agreement with Paul Kang, President of Alta Companies LTD, for transitional consulting services. Mr. Kang was a former director and officer of the Company. The Company paid Alta $99,000 and began paying Mr. Kang $12,500 monthly starting February 2025.

Stakeholder Impact

• Shareholders face significant risk of dilution if capital is raised through equity offerings, and potential loss of investment if the company ceases operations or seeks bankruptcy protection.
• Employees may face uncertainty due to ongoing financial distress, potential restructuring, and the risk of job losses.
• Creditors and suppliers may face risks related to the company's ability to meet its financial obligations.
• The company's ability to continue operations impacts its partners and collaborators, such as GPCR Therapeutics.

Next Steps

• Continue evaluation of strategic alternatives, including potential acquisitions, financings, strategic partnerships, and other business combination opportunities.
• Submit and obtain approval for the Plan of Compliance from Nasdaq to address the stockholders' equity shortfall.
• Address the unlawful detainer action filed by Dren Bio.
• Seek additional equity and/or debt financings, strategic transactions, or other sources of capital.
• Continue supporting GPCR USA's clinical development programs.

Key Dates

Recommendation

The filing indicates severe financial distress with a going concern warning, insufficient liquidity, and ongoing legal challenges. While cost reductions are noted, the fundamental issues of cash runway and the need for significant capital raise under challenging market conditions, coupled with Nasdaq equity concerns, present substantial downside risk for investors.

Keywords

biotechnology, clinical development, strategic alternatives, going concern, Nasdaq listing, cash burn, financial distress, GPCR Therapeutics